NCT03497260

Brief Summary

To determine and compare the time-to-hypoglycaemia (defined as plasma glucose \<3.9mmol/L) in individuals with type 1 diabetes treated with ultra-Long acting insulin degludec during aerobic exercise with or without prior ingestion of a single oral fructose load.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 6, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 13, 2018

Completed
9 months until next milestone

Study Start

First participant enrolled

January 4, 2019

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 6, 2019

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 8, 2019

Completed
Last Updated

September 20, 2019

Status Verified

September 1, 2019

Enrollment Period

8 months

First QC Date

April 6, 2018

Last Update Submit

September 19, 2019

Conditions

Keywords

Type 1 Diabetes, Fructose, Exercise, Hypoglycaemia, Degludec

Outcome Measures

Primary Outcomes (1)

  • Time (in minutes) to hypoglycaemia (plasma glucose <3.9mmol/l)

    The development of hypoglycaemia will be determined by repeated measurement of plasma glucose.

    From time point 0 minutes (initiation of exercise) to time point 60 minutes (completion of exercise) or development of hypoglycaemia

Secondary Outcomes (15)

  • Glucose levels before exercise

    Time point -30 minutes until time point 0 minutes (initiation of exercise)

  • Glucose levels during exercise

    From time point 0 minutes until time point 60 minutes (completion of exercise) or development of hypoglycaemia

  • Glucose levels after exercise

    From time point 0 minutes until time point 90 minutes

  • Lactate levels before exercise

    From time point -30 minutes until time point 0 minutes (initiation of exercise)

  • Lactate levels during exercise

    From time point 0 minutes until time point 60 minutes (completion of exercise) or development of hypoglycaemia

  • +10 more secondary outcomes

Study Arms (2)

Fructose in water first, water only second

EXPERIMENTAL

Intake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit

Dietary Supplement: FructoseOther: Plain water

Water only first, Fructose in water second

EXPERIMENTAL

Intake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit

Dietary Supplement: FructoseOther: Plain water

Interventions

FructoseDIETARY_SUPPLEMENT

Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.

Fructose in water first, water only secondWater only first, Fructose in water second

Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.

Fructose in water first, water only secondWater only first, Fructose in water second

Eligibility Criteria

Age18 Years - 45 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Type 1 diabetes as defined by the World Health Organization (WHO) for at least 1 year or confirmed negative C-peptide (\<100pmol/l with concomitant blood glucose \>4 mmol/l)
  • Male subjects aged between 18-45 years
  • HbA1c \<8.0% (64mmol/mol) based on analysis from the central laboratory unit of the University Hospital Bern.
  • Basal/Bolus-insulin regimen with insulin degludec for at least 3 months, with good knowledge of insulin self-management
  • Regular physical activity (at least 30 min of moderate exercise 3 times weekly)
  • Written informed consent

You may not qualify if:

  • Relevant diabetic complications as judged by the investigator
  • Total daily insulin dose \>2 IU/kg/day
  • Hypoglycaemia unawareness (Gold score \> 4) or any episode of severe hypoglycaemia as defined by the American Diabetes Association within the last 6 months
  • Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  • Current treatment with drugs known to interfere with metabolism, e.g. systemic corticosteroids, statins etc.
  • Known fructose-intolerance or malabsorption
  • Known allergy to one of the study drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital

Bern, 3010, Switzerland

Location

Related Publications (1)

  • Kosinski C, Herzig D, Laesser CI, Nakas CT, Melmer A, Vogt A, Vogt B, Laimer M, Bally L, Stettler C. A Single Load of Fructose Attenuates the Risk of Exercise-Induced Hypoglycemia in Adults With Type 1 Diabetes on Ultra-Long-Acting Basal Insulin: A Randomized, Open-Label, Crossover Proof-of-Principle Study. Diabetes Care. 2020 Sep;43(9):2010-2016. doi: 10.2337/dc19-2250. Epub 2020 Jun 26.

MeSH Terms

Conditions

Diabetes Mellitus, Type 1Diabetes ComplicationsMotor ActivityHypoglycemia

Interventions

Fructose

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesBehavior

Intervention Hierarchy (Ancestors)

HexosesMonosaccharidesSugarsCarbohydratesKetoses

Study Officials

  • Christoph Stettler, MD

    Inselspital, Bern University Hospital, University of Bern

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 6, 2018

First Posted

April 13, 2018

Study Start

January 4, 2019

Primary Completion

September 6, 2019

Study Completion

September 8, 2019

Last Updated

September 20, 2019

Record last verified: 2019-09

Locations